Overview
LFCR market data
Price History
LFCR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.09 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -29.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.63 – $8.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $180.6M · P/B 9.00 · P/S 1.10.
Company News
Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M EstimateBenzinga · Aug 5, 2026, 11:18 AM
8-K filing — LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)SEC EDGAR · Aug 5, 2026, 11:17 AM
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M EstBenzinga · Aug 5, 2026, 11:06 AM
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5Benzinga · Jun 16, 2026, 12:35 PM
Lifecore Biomedical Announced It Has Signed A New Agreement With A Global Pharmaceutical CompanyBenzinga · Jun 15, 2026, 11:25 AM
Lifecore Biomedical Signs Manufacturing Services Agreement To Perform Process Development And Technical Transfer Services In Support Of Anticipated Commercial Manufacturing Upon Regulatory ApprovalBenzinga · Jun 2, 2026, 11:07 AM